NCT07109219 - Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 28, 2028

Study Completion Date

July 3, 2028

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

COMBINATION_PRODUCT

AZD4512 monotherapy

Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22

Trial Locations (22)

106

Research Site, Taipei

3000

Research Site, Melbourne

3722

Research Site, Seoul

32224

Research Site, Jacksonville

37007

Research Site, Salamanca

37203

Research Site, Nashville

39008

Research Site, Santander

40705

Research Site, Taichung

46026

Research Site, Valencia

52242

Research Site, Iowa City

60611

Research Site, Chicago

77030

Research Site, Houston

91010

Research Site, Duarte

M5G 1X6

Research Site, Toronto

113-8677

Research Site, Bunkyō City

104-0045

Research Site, Chūōku

03080

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

08035

Research Site, Barcelona

NW1 2PG

Research Site, London

M20 4BX

Research Site, Manchester